Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design
- Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders
- Unique combination of novel technologies to enhance GPCR drug discovery and expand capabilities into wider drug target universe
News provided by
Share this article
Share this article
TOKYO and CAMBRIDGE, England, Dec. 22, 2020 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565), a world leader in GPCR-focused structure-based drug design and development, and Captor Therapeutics SA ( Captor ; Wroclaw, Poland and Allschwil, Switzerland), a European leader in targeted protein degradation, have entered a strategic technology collaboration focused on the discovery and development of novel small molecules that target the degradation of disease-associated G protein-coupled re